Chrisann Kyi, MD
Gynecologic Medical Oncologist & Early Drug Development Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Assistant Attending Physician
I am a medical oncologist who specializes in treating gynecologic cancers. I have an expertise in caring for women with ovarian cancer, uterine (endometrial) cancer, and cervical cancer.
I am part of a team of experts, including surgeons, radiation oncologists, pathologists, and nurses. We are dedicated to providing comprehensive, compassionate, and personalized care for women with these cancers.
Read more
Like so many people, I too have been personally impacted by cancer in close family and friends. My experiences led me to pursue a career in medical oncology. Now, they motivate me each day as I do everything I can to help my patients.
My research focuses on understanding the genetic and immunologic basis of cancer. I am especially dedicated to studying personalized immunotherapy approaches. These include cancer vaccines and oncolytic viruses. I am actively involved in developing early-phase clinical trials to evaluate new immunotherapy treatments for gynecologic cancers. In addition to being part of the Gynecologic Medical Oncology Service, I have a joint appointment to the Immune Therapy Clinic. I have received research funding from the American Society of Clinical Oncology and the American Association for Cancer Research.
Women who are diagnosed with a gynecologic cancer often take on a tremendous amount of information, stress, and added responsibility on top of their already busy lives. I am committed to helping my patients and their families deal with the medical as well as emotional issues related to a cancer diagnosis, treatment, prognosis, and survival. After our clinic visits, I hope my patients feel more confident and reassured as we work together toward the best treatment plan. As their medical oncologist, I want my patients to know I am their advocate, and through my care, hope to relieve some of the burden of their cancer diagnosis.
A gynecologic (GY-neh-kuh-LAH-jik) medical oncologist is a cancer doctor who specializes in gynecologic cancers. This includes cervical, fallopian tube, ovarian, uterine (endometrial), vaginal, and vulvar cancers.
An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.
My Specialties
- Immunotherapy
- Early Phase Clinical Trials
- Ovarian Cancer
- Uterine (Endometrial) Cancer
- Cervical Cancer
Education
- MD, Georgetown School of Medicine
Residencies
- Internal Medicine – New York-Presbyterian/Weill Cornell Medical Center
Awards and Honors
- Young Investigator Award: Career Development Award, American Society of Clinical Oncology (2019)
- Young Investigator Award, American Society of Clinical Oncology (2017)
Fellowships
- Hematology & Medical Oncology – Icahn School of Medicine Mount Sinai
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Kyi sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Kyi
- A Phase 1/2A Study of LB101 Immunotherapy in People With Solid Tumors
- A Phase 1B Study of E7386 and Lenvatinib in People With Advanced Endometrial Cancer
- A Phase 2 Study of IMNN-001 on Second-Look Surgery in Combination With Bevacizumab and Chemotherapy in People Newly Diagnosed With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
- Clinical Trials Co-Investigated by Dr. Kyi
- A Phase 1/2 Study of HST-1011 Immunotherapy in People With Solid Tumors
Read more
- A Phase 1/2 Study of STAR0602 in People With Solid Tumors
- A Phase 1B/2 Study of ACR-368 Alone and with Gemcitabine in People with Ovarian, Endometrial, or Urothelial Cancer
- A Phase 2 Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
- A Phase I Study of IMC-F106C in People with Advanced Solid Tumors Containing Specific Proteins
- A Phase I Study of RP-6306 to Treat Advanced Solid Tumors with Certain Genetic Changes
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Kyi’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Chrisann Kyi discloses the following relationships and financial interests:
-
OncLive
Professional Services and Activities
-
Society for Immunotherapy of Cancer
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.